TY - JOUR
T1 - Precios, disponibilidad y asequibilidad de insulina en farmacias públicas y privadas en Perú
AU - Tenorio-Mucha, Janeth
AU - Lazo-Porras, María
AU - Hidalgo-Padilla, Liliana
AU - Beran, David
AU - Ewen, Margaret
N1 - Publisher Copyright:
© 2019 Pan American Health Organization. All rights reserved.
PY - 2019
Y1 - 2019
N2 - Objective. Measure and compare the price, availability, and affordability of insulin and metformin in public and private pharmacies in six regions of Peru. Methods. Cross-sectional study using the World Health Organization/Health Action International (WHO/HAI) revised methodology. Public and private pharmacies in six regions of Peru were surveyed. Data were collected on availability and prices for insulin (all types) and 850 mg metformin. Availability is expressed as percentages and prices are reported in medians. Affordability is defined as the number of days that a person must work at minimum wage to cover the cost of one month of treatment. Results. Availability in public pharmacies is 63.2% for regular insulin and 68.4% for NPH (isophane) insulin, but differences in availability were observed between levels of care and between regions. Private pharmacies have a greater variety of insulin, but availability is less than 11%. The median price of human insulin was three to four times higher in private pharmacies than in public pharmacies. In comparison, availability of metformin was 89.5% in public pharmacies and 77.7% in private ones. Affordability in public pharmacies for one month of treatment with human insulin or generic metformin is less than one day’s wages. Conclusions. The price for human insulin and generic metformin in public pharmacies is affordable. However, efforts are needed to improve their availability in the different regions and levels of care.
AB - Objective. Measure and compare the price, availability, and affordability of insulin and metformin in public and private pharmacies in six regions of Peru. Methods. Cross-sectional study using the World Health Organization/Health Action International (WHO/HAI) revised methodology. Public and private pharmacies in six regions of Peru were surveyed. Data were collected on availability and prices for insulin (all types) and 850 mg metformin. Availability is expressed as percentages and prices are reported in medians. Affordability is defined as the number of days that a person must work at minimum wage to cover the cost of one month of treatment. Results. Availability in public pharmacies is 63.2% for regular insulin and 68.4% for NPH (isophane) insulin, but differences in availability were observed between levels of care and between regions. Private pharmacies have a greater variety of insulin, but availability is less than 11%. The median price of human insulin was three to four times higher in private pharmacies than in public pharmacies. In comparison, availability of metformin was 89.5% in public pharmacies and 77.7% in private ones. Affordability in public pharmacies for one month of treatment with human insulin or generic metformin is less than one day’s wages. Conclusions. The price for human insulin and generic metformin in public pharmacies is affordable. However, efforts are needed to improve their availability in the different regions and levels of care.
KW - Access to essential medicines and health technologies
KW - Drug price
KW - Insulin
KW - Metformin
KW - Peru
UR - http://www.scopus.com/inward/record.url?scp=85111647846&partnerID=8YFLogxK
U2 - 10.26633/RPSP.2019.85
DO - 10.26633/RPSP.2019.85
M3 - Artículo
AN - SCOPUS:85111647846
SN - 1020-4989
VL - 43
JO - Revista Panamericana de Salud Publica/Pan American Journal of Public Health
JF - Revista Panamericana de Salud Publica/Pan American Journal of Public Health
ER -